Legal & General Group’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.34K | Hold |
421
| – | – | ﹤0.01% | 3350 |
|
|
2025
Q4 | $1.81K | Hold |
421
| – | – | ﹤0.01% | 3378 |
|
|
2025
Q3 | $16.4K | Buy |
421
+111
| +36% | +$3.16K | ﹤0.01% | 3125 |
|
|
2025
Q2 | $7.23K | Buy |
+310
| New | +$7.33K | ﹤0.01% | 3353 |
|
|
2024
Q2 | – | Sell |
-120
| Closed | -$3.94K | – | 3527 |
|
|
2024
Q1 | $3.94K | Hold |
120
| – | – | ﹤0.01% | 3313 |
|
|
2023
Q4 | $3.22K | Hold |
120
| – | – | ﹤0.01% | 3348 |
|
|
2023
Q3 | $7.28K | Hold |
120
| – | – | ﹤0.01% | 3321 |
|
|
2023
Q2 | $12.3K | Sell |
120
-2,529
| -95% | -$348K | ﹤0.01% | 3277 |
|
|
2023
Q1 | $468K | Sell |
2,649
-340
| -11% | -$114K | ﹤0.01% | 2326 |
|
|
2022
Q4 | $1.16M | Buy |
2,989
+63
| +2% | +$23.9K | ﹤0.01% | 2111 |
|
|
2022
Q3 | $986K | Buy |
2,926
+182
| +7% | +$65.9K | ﹤0.01% | 2151 |
|
|
2022
Q2 | $902K | Sell |
2,744
-40
| -1% | -$14K | ﹤0.01% | 2196 |
|
|
2022
Q1 | $1.22M | Sell |
2,784
-25
| -0.9% | -$10.3K | ﹤0.01% | 2172 |
|
|
2021
Q4 | $1.23M | Buy |
2,809
+102
| +4% | +$51.3K | ﹤0.01% | 2190 |
|
|
2021
Q3 | $1.51M | Buy |
2,707
+177
| +7% | +$88.8K | ﹤0.01% | 2146 |
|
|
2021
Q2 | $1.3M | Buy |
2,530
+2,321
| +1,111% | +$1.47M | ﹤0.01% | 2137 |
|
|
2021
Q1 | $163K | Hold |
209
| – | – | ﹤0.01% | 2494 |
|
|
2020
Q4 | $113K | Hold |
209
| – | – | ﹤0.01% | 2553 |
|
|
2020
Q3 | $96K | Sell |
209
-51
| -20% | -$29.6K | ﹤0.01% | 2504 |
|
|
2020
Q2 | $160K | Buy |
260
+15
| +6% | +$8.29K | ﹤0.01% | 2407 |
|
|
2020
Q1 | $116K | Sell |
245
-47
| -16% | -$25.5K | ﹤0.01% | 2373 |
|
|
2019
Q4 | $170K | Buy |
292
+36
| +14% | +$25.3K | ﹤0.01% | 2434 |
|
|
2019
Q3 | $168K | Buy |
256
+26
| +11% | +$21.6K | ﹤0.01% | 2385 |
|
|
2019
Q2 | $178K | Buy |
230
+67
| +41% | +$47.1K | ﹤0.01% | 2376 |
|
|
2019
Q1 | $115K | Buy |
163
+9
| +6% | +$5.39K | ﹤0.01% | 2451 |
|
|
2018
Q4 | $72K | Hold |
154
| – | – | ﹤0.01% | 2562 |
|
|
2018
Q3 | $132K | Buy |
154
+41
| +36% | +$29.6K | ﹤0.01% | 2433 |
|
|
2018
Q2 | $78K | Sell |
113
-27
| -19% | -$13.7K | ﹤0.01% | 2571 |
|
|
2018
Q1 | $62K | Sell |
140
-56
| -29% | -$27.2K | ﹤0.01% | 2650 |
|
|
2017
Q4 | $88K | Sell |
196
-33
| -14% | -$15K | ﹤0.01% | 2648 |
|
|
2017
Q3 | $112K | Buy |
229
+30
| +15% | +$15K | ﹤0.01% | 2587 |
|
|
2017
Q2 | $118K | Buy |
199
+19
| +11% | +$12.1K | ﹤0.01% | 2518 |
|
|
2017
Q1 | $117K | Sell |
180
-7
| -4% | -$3.74K | ﹤0.01% | 2463 |
|
|
2016
Q4 | $63K | Buy |
187
+84
| +82% | +$27K | ﹤0.01% | 2809 |
|
|
2016
Q3 | $30K | Hold |
103
| – | – | ﹤0.01% | 2738 |
|
|
2016
Q2 | $18K | Hold |
103
| – | – | ﹤0.01% | 2857 |
|
|
2016
Q1 | $23K | Hold |
103
| – | – | ﹤0.01% | 2651 |
|
|
2015
Q4 | $59K | Buy |
+103
| New | +$56.5K | ﹤0.01% | 2371 |
|
Other funds holding TVRD
SPC
VCM
AFG
SAM
DWAM
Legal & General Group's TVRD Position: Q1 2026 in Review
Legal & General Group held its Tvardi Therapeutics (TVRD) position steady in Q1 2026 at 421 shares worth $1.34K. The position accounts for ﹤0.01% of the portfolio, ranked #3350.
Legal & General Group first reported a position in TVRD in Q4 2015 and has held it in 38 quarters since. The position peaked at $1.51M in Q3 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.
- Legal & General Group held 421 shares of Tvardi Therapeutics worth $1.34K as of Q1 2026.
- Legal & General Group left its Tvardi Therapeutics share count unchanged in Q1 2026.
- Tvardi Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3350 holding.
- Legal & General Group first reported a position in Tvardi Therapeutics in Q4 2015 and has held it in 38 quarters since.
- Legal & General Group's Tvardi Therapeutics position peaked at $1.51M in Q3 2021.
- 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.
Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.